Almost every drug discovery endeavor around the world uses more or less sophisticated automation platforms for so called high throughput screening approaches. These technologies are most often focused on the discovery of small molecule compounds and evolved for more than the last fifteen years, resulting in highly adopted and specialized automation platforms.
In contrast the use of laboratory high throughput automation for the discovery of biological drugs needs fundamentally different setups and is relatively young and less evolved. We will describe the design and provide examples of the next generation screening platform at Bayer Global Biologics.
Michael Strerath, Bayer Healthcare